[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuro-degenerative-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuro-degenerative-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,40,95,122,151,196,219,249,281,313,361,402,423],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100599675","3d-printers-for-autonomy-in-the-care-of-inpatients-in-continuing-and-rehabilitation-care-100599675",false,"NCT07087574","3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care","AUTARI-3D","Inclusion Criteria:\n\n1. Patient hospitalized in a Continuing Care and Rehabilitation department ;\n2. Patient suffering from a neurodegenerative disease (Mini Mental Test score \\> 15);\n3. Age ≥ 18 years;\n4. Patient with a score ≥ 3 on the \"Eating\" criterion of the Katz scale (corresponding to the need for at least partial assistance with meals).\n\nExclusion Criteria:\n\n1. Opposition of the patient or his relatives to participating in the research ;\n2. Patient unable to use hands to eat (amputation, paralysis, etc.);\n3. Patient under court protection;\n4. Pregnant, parturient or breast-feeding woman;\n5. Any other reason which, in the opinion of the investigator, could interfere with the evaluation of the study objectives.","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients hospitalized in Continuing and Rehabilitation Care Units (CRCU) are for the most part elderly people suffering from neurodegenerative diseases, requiring individual, personalized rehabilitation care.\n\nSome of these patients require ergotherapy to help them regain functional ability in everyday activities. The ergotherapist organizes therapeutic activities tailored to patients' needs, with a view to optimizing their level of autonomy.\n\nLoss of autonomy is closely linked to nutritional status, which often tends towards malnutrition in patients admitted to CRCU, with deleterious consequences for the elderly. The use of technical aids to facilitate meal-taking could be a way of alleviating undernutrition. A technical aid is defined as a material aid that enables elderly or disabled people to compensate for a limitation in activity.\n\nThe investigators are interested in the use of adapted cutlery, as patients often find it difficult to eat on their own, being unable to grip their cutlery correctly. Commercially adapted cutlery exists, but it is expensive and difficult to use because it is not adapted to each patient (standard size) and is too heavy. What's more, the investigators observe that their use does not necessarily improve the patient's degree of dependence, generally measured by the Katz scale.\n\nThe idea of the team of ergotherapist is to offer ergonomic cutlery handles with diameters adapted to patients' degree of prehension. They offer handles with diameters of 25 mm, 30 mm, 35 mm and 40 mm. The diameter is customized according to the hand's flexion capacity, as assessed by a joint and functional assessment. What's original about these technical aids is that they are designed from thermoformable materials with the help of a 3 Dimension printer and Computer-Aided Design and Manufacturing software, in partnership with the Fablab (Fabrication laboratory) in Toulon and the Hyères media library. They have the added advantage of being lightweight and inexpensive.",[26],"Neuro-Degenerative Disease","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-16","ACTUAL",{"date":33,"type":31},"2026-03-30",{"date":35,"type":20},"2027-10",{"name":37,"class":38},"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":67,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",true,{"count":49,"type":20},1000000,"OBSERVATIONAL","The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[53,54,55,56,57,58,59,60,61,62,63,64,65,26,66],"Aging","Aging Well","All-Cause Mortality","Mortality","Metabolic Syndrome","Cardiovascular Diseases","Cognitive Dysfunction","Musculoskeletal Diseases","Neoplasms","Frailty","Activities of Daily Living","Health-Related Quality of Life","Disability Physical","Dementia",[68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Longevity","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Surrogate Endpoint Validation","Mortality Prediction","Functional Decline","Healthspan","Life Expectancy","Biological Aging","Preventive Screening","Longitudinal Cohort","Biomarker Validation","Human Performance","Population Health","Centenarian","2026-06-09",{"date":86,"type":31},"2026-06-11",{"date":88,"type":31},"2025-02-09",{"date":90,"type":20},"2099-12-31",{"name":92,"class":93},"Longevity Metrics, Inc.","INDUSTRY",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":94},"100638270","walking-and-thinking---brain-activity-during-complex-walking-in-stroke-100638270","NCT07624630","Walking and Thinking - Brain Activity During Complex Walking in Stroke","Inclusion Criteria:\n\n* 18 years or older\n* with a stroke ≥6 months confirmed by a clinical diagnosis\n* with the ability to walk with or without a walking aid for ≥ 5 min\n\nExclusion Criteria:\n\n* Individuals post stroke with cognitive impairment\n* severe neglect\n* global aphasia affecting the ability to provide written informed consent\n* severe perceptual problems or severe freezing of gait",{"count":102,"type":20},50,"Everyday life requires individuals to function in complex environments and perform tasks that involve the integration of motor and cognitive abilities. However, stroke often leads to impairments in motor-cognitive interaction, which can negatively affect mobility, balance, attention, and the ability to live independently. Although motor-cognitive performance has been identified as an important rehabilitation target after stroke, limited knowledge exists regarding the underlying brain function associated with these difficulties and how rehabilitation and exercise interventions can best address them.\n\nImproving treatment for motor-cognitive difficulties after stroke, such as dual-task walking and navigation, remains a major challenge. An important step is developing assessment methods that accurately capture these impairments in ecologically valid settings that reflect real-world mobility demands. The investigators therefore aim to explore brain function during complex walking after stroke by investigating motor-cognitive performance and its neural correlates during three walking conditions: dual-task walking, navigation, and a combination of both. Non-invasive measures of brain activity using functional near-infrared spectroscopy (fNIRS) together with advanced real-time gait analysis will be used to better understand how stroke affects motor-cognitive functioning during complex walking tasks.",[105,53,26,106],"Stroke","Gait Impairment in Stroke Patients",[105,108,109,110,111,112],"Dual task walking","navigated walking","motor-cognitive interference","funtional Near Infrared Spectroscopy (fNIRS)","brain funtion","2026-06-01",{"date":115,"type":31},"2026-06-03",{"date":117,"type":20},"2026-08-01",{"date":119,"type":20},"2027-07-01",{"name":121,"class":38},"Karolinska Institutet",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100623452","phase-1-kamlanoflast-in-amyotrophic-lateral-sclerosis-100623452","NCT07396818","Kamlanoflast In Amyotrophic Lateral Sclerosis","A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis","Inclusion Criteria:\n\n1. Diagnosis of definite, probable, laboratory-supported probable, or possible ALS by revised El Escorial research criteria.\n2. Ages 18 to 75 years.\n3. Onset of weakness within three years of study enrollment.\n4. ALS with progression, characterized either by:\n\ni. a reduction of 0.5 points per month or greater on the ALS Functional Rating Scale-Revised (ALSFRS-R), which will be calculated based on (most recent ALSFRS-R at least 12 weeks from screening - ALSFRS-R at screening)\u002Ftime interval; or ii. a calculated progression rate: (48 - ALSFRS-R at \"time of diagnosis\") \u002F duration from onset to diagnosis (month) that is 0.5 points per month or greater.\n\ne) Plasma NfL levels ≥ 2 times the upper limit of the age-specific reference values for normal at the measuring laboratory at screening.\n\nf) Capable of providing informed consent. g) Capable and willing to follow study protocol. h) Ability to swallow pills and liquids at the time of the screening visit and, in the investigator's opinion have the ability to swallow for the duration of the study OR can be fed via a Gastrostomy (G) tube or Percutaneous Endoscopic capacity (PEG) tube.\n\ni) Slow vital capacity (SVC) \\> 65% of predicted value for gender, height, and age (participants perform SVC for three trials and the best SVC will be used).\n\nj) Females of childbearing potential must agree to abstain from sex or use adequate method of contraception for the duration of the study period and for 28 days after the last dose of study drug.\n\nk) Males must agree to abstain from sex or use adequate method of contraception for the duration of the study period and for 28 days after the last dose of study drug.\n\nl) If an approved therapy for ALS is used during the study, a steady dose must be used as follows: i. Participants who do not currently receive riluzole and do not plan to receive riluzole during the study period. Participants receiving riluzole are on a stable dose for at least 4 weeks before enrollment. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study.\n\nii. Participants who do not currently receive edaravone and do not plan to receive edaravone during the study period. Participants receiving edaravone must have completed at least 1 cycle of treatment before enrollment and are expected to continue edaravone treatment throughout the duration of the study.\n\nExclusion Criteria:\n\n1. Inability to follow the study protocol, based on the investigator's assessment.\n2. Pregnant or nursing women.\n3. Recently（within 28 days）received other experimental treatments.\n4. Presence of any active infections or inflammatory diseases at the time of enrollment that may confound the assessment of levels of inflammatory markers.\n5. Taking any medication or supplements with anti-inflammatory effects, including but not limited to prednisone, colchicine, or curcumin.\n6. Taking Qalsody (tofersen).\n7. Taking any medications containing nucleotide reverse transcriptase inhibitors (NRTIs), including but not limited to Abacavir, Emtricitabine, Lamivudine, or Zidovudine; trade names Atripla, Biktarvy, Cimduo, Combivir, Complera, Delstrigo, Descovy, Dovato, Emtriva, Epivir, Epzicom, Genvoya, Odefsey, Retrovir, Stribild, Symfi, Symtuza, Triumeq, Trizivir, Truvada, Ziagen.\n8. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to investigator's judgment (e.g., cardiovascular instability, systemic infection), or clinically significant laboratory abnormality.\n9. Clinically significant abnormal liver or kidney function at baseline (pre-dose). The following values \\[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m2\\] are exclusionary regardless of clinical symptoms.\n10. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the investigator's opinion.\n11. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.\n12. Non-invasive ventilation, tracheostomy, oxygen supplementation for primary pulmonary pathology.\n13. Current \u002F anticipated need of diaphragm pacing system (DPS).\n14. History of prior AAV gene therapy for any indication;\n15. Presence of any clinically relevant diseases that, in the research team's opinion, would prevent the subject from completing the study, including but not limited to severe cognitive dysfunction or medical conditions other than ALS that affect physical function or life expectancy.\n16. Plan to move away from the study site within the next 6 months.","75 Years",{"count":131,"type":20},40,[133,134],"PHASE1","PHASE2","This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.",[137,138,26,139,140],"ALS (Amyotrophic Lateral Sclerosis)","ALS","Neuro-Degenerative Diseases","Motor Neuron Disease (MND)","NOT_YET_RECRUITING","2026-02-02",{"date":144,"type":31},"2026-02-09",{"date":146,"type":20},"2026-02",{"date":148,"type":20},"2027-01",{"name":150,"class":93},"Inflammasome Therapeutics",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":160,"conditions":161,"keywords":176,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":94},"100303705","retinal-imaging-in-neurodegenerative-disease-100303705","NCT03233646","Retinal Imaging in Neurodegenerative Disease","Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study","Inclusion Criteria:\n\n* Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)\n* Adults without neurodegenerative disease\n\nExclusion Criteria:\n\n* Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.\n* Eyes that have had intraocular surgery, other than cataract surgery.\n\nIf two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.",{"count":159,"type":20},2000,"This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.",[162,163,164,165,166,167,168,169,170,171,172,173,174,26,175],"Alzheimer's Disease","Mild Cognitive Impairment","Parkinson's Disease","Multiple Sclerosis","Huntington Disease","Lewy Body Dementia","Frontotemporal Dementia","Amyotrophic Lateral Sclerosis (ALS)","APOE-4 Positive","Traumatic Brain Injury","Concussion","Post-Traumatic Stress Disorder","Down Syndrome","Normal Cognition",[177,178,179,180,181,182,183,184,185,186,187],"OCT angiography (OCTA)","Optical Coherence Tomography (OCT)","Vessel Density","Superficial Capillary Plexus","Retinal microvasculature","Scanning Laser Ophthalmoscopy","Ultra-widefield (UWF) Imaging","Perfusion Density","Retinal Nerve Fiber Layer","Ganglion Cell Inner Plexiform Layer","Choroidal Vascularity Index",{"date":189,"type":31},"2026-02-04",{"date":191,"type":31},"2017-07-20",{"date":193,"type":20},"2026-12-31",{"name":195,"class":38},"Duke University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100527733","a-prospective-natural-history-and-outcome-measure-discovery-study-of-charcot-marie-tooth-disease-type-4j-100527733","NCT06151600","A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J","CMT4J","Inclusion Criteria:\n\n1. Male or female, all ages\n2. A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and\u002For likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and\u002For likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists.\n3. Informed consent from patients 18 years or older who are able to provide consent and from caregivers; parent(s)\u002Fguardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent\n4. Informed assent of patients younger than 18 years at Screening who are able to provide assent\n5. Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits\n\nExclusion Criteria:\n\n1. Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype\n2. Current participation in an interventional or therapeutic study\n3. Receiving an investigational drug within 90 days of the Baseline Visit\n4. Prior or current treatment with gene or stem cell therapy\n5. Any other diseases which may significantly interfere with the assessment of CMT4J\n6. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study",{"count":204,"type":20},20,"This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J. The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations. Subject visits will occur every 12 months + 4 weeks for up to 2 years.",[207,26,208],"Peripheral Neuropathy","Neuromuscular Diseases","2026-01-20",{"date":211,"type":31},"2026-01-22",{"date":213,"type":31},"2024-07-29",{"date":215,"type":20},"2032-03-01",{"name":217,"class":93},"Elpida Therapeutics SPC",3,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":233,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":94},"100617295","eccentric-cycling-in-multiple-sclerosis-rehabilitation-100617295","NCT07316764","Eccentric Cycling in Multiple Sclerosis Rehabilitation","Eccentric Cycling : a New Training Modality in Multiple Sclerosis Rehabilitation","Inclusion Criteria:\n\n* Diagnosis of multiple sclerosis\n* Multiple sclerosis: EDSS score \\\u003C 7\n* Age under 75 years\n* Stable disease state\n* Written medical clearance authorizing participation\n* Legal adult status\n* Written informed consent, with demonstrated understanding of the consent form (via a few specific questions)\n* Ability to mobilize independently (e.g., transfers, walking)\n\nExclusion Criteria:\n\n* One or more contraindications to physical activity\n* Significant comorbidities\n* Current hospitalization or undergoing changes in medication\n* Active flare-up",{"count":227,"type":20},60,[23],"The project aims to optimise functional rehabilitation programmes for people with multiple sclerosis.\n\nInvestigators are proposing eccentric cycling as a new exercise modality for treating these patients.\n\nBased on previous results in healthy subjects, investigators will attempt to define the optimal parameters of this new modality (in terms of duration, intensity, frequency, etc.).\n\nInvestigators also aim to demonstrate the effectiveness of this training (compared to conventional training) in improving muscle function, functional capacity, perception of chronic fatigue, quality of life, physical condition, and neurological and cognitive function.",[165,231,26,232],"Rehabilitation","Neurorehabilitation",[234,235,236,237,238,239],"eccentric cycling","multiple sclerosis","eccentric training","neurorehabilitation","physical therapy","neuro-degenerative disease","2025-12-23",{"date":242,"type":31},"2026-01-05",{"date":244,"type":20},"2026-01",{"date":246,"type":20},"2026-12",{"name":248,"class":38},"University of Liege",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":268,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":280},"100368581","phase-2-cobimetinib-in-refractory-langerhans-cell-histiocytosis-lch-and-other-histiocytic-disorders-100368581","NCT04079179","Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders","A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.","NACHO-COBI","INCLUSION CRITERIA:\n\nAge at study entry\n\n* For Group 1: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment\n* For Group 2: Participant may be at least 6 months of age at the time of enrollment\n* For Group 3: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment\n* For Group 4: Participant must be 21 years of age or older at the time of enrollment\n* Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet which may be taken by mouth or other enteral route such as nasogastric or gastric tube.\n* Biopsy proven LCH -AND\n* Failure of at least front-line therapy for LCH with evaluable disease. -OR\n* Diagnosis of LCH-associated neurodegenerative disease with radiologic or clinical progression within the past 3 months. -OR\n* Biopsy proven JXG, ECD, RDD, histiocytic sarcoma, or other histiocytic lesion (newly diagnosed or relapsed\u002Frefractory disease) with evaluable active disease.\n\nPerformance Level:\n\n-Karnofsky ≥ 50% for patients \\> 16 years of age and Lansky ≥ 50% for patients ≤ 16 years of age.\n\nAdequate Hematologic Function Defined as:\n\n* ANC ≥ 0.75 x 10\\^9\u002FL (unsupported\u002Fwithout growth factor stimulant)\n* Platelet count ≥ 75 x 10\\^9\u002FL (unsupported\u002Fwithout transfusion within the past 7 days).\n* Patients with marrow disease must have platelet count of \\>\u002F= 75 x 10\\^9\u002FL (transfusion support allowed) and must not be refractory to platelet transfusions.\n* Hemoglobin ≥ 8 g\u002FdL (unsupported\u002Fwithout transfusion within the past 7 days)\n* Patients with marrow disease must have hemoglobin ≥ 8 g\u002FdL (transfusion support allowed).\n\nAdequate Renal Function Defined as:\n\n\\- Calculated creatinine clearance (or radioisotope GFR) ≥ 70 mL\u002Fmin\u002F1.73m\\^2 or serum creatinine based on age\u002Fgender as follows:\n\nMaximum Serum Creatinine (mg\u002FdL) Age 2 to \\\u003C 6 years: Male 0.8 mg\u002FdL, Female 0.8; 6 to \\\u003C 10 years: Male 1 mg\u002FdL,Female 1; 10 to \\\u003C 13 years: Male 1.2 mg\u002FdL; Female 1.2; 13 to \\\u003C 16 years: Male 1.5 mg\u002FdL ; Female 1.4; ≥ 16 years: Male 1.7 mg\u002FdL; Female 1.4;\n\nAdequate Liver Function Defined as:\n\n* Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age\n* AST and ALT ≤ 3x ULN (≤ 5 x ULN for participants with liver involvement)\n* Serum albumin ≥ 2 g\u002FdL.\n\nFor patients with liver disease caused by histiocytic disorder:\n\n• Patients may be enrolled with abnormal bilirubin, AST, ALT and albumin with documentation of histiocytic liver disease.\n\nAdequate Cardiac Function Defined as:\n\n\\- Fractional shortening (FS) of ≥ 30% or ejection fraction of ≥ 50% by echocardiogram at baseline, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to enrollment. Depending on institutional standard, either FS or LVEF is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above\n\nPregnancy\u002FBirth Control\n\n* Female patients of childbearing potential require a negative urine or serum pregnancy test for eligibility and again at database registration, if more than 2 weeks has elapsed.\n* Female patients of childbearing potential must agree to follow the contraceptive requirements using two forms of effective contraceptive methods for the duration of the study treatment. Male patients with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) must agree to use two forms of effective methods of contraception (one of which must be a barrier method) during the treatment period and for at least 3 months after the last dose of the study drug to avoid pregnancy and\u002For potential adverse effects on a developing embryo. Agreement to true abstinence (not periodic abstinence or withdrawal method) is an acceptable method of birth control.\n\nEXCLUSION CRITERIA:\n\n\\- Prior and Concomitant Use of Drugs with CYP3A4 inducing\u002Finhibiting activity: Patient taking strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment, including but not limited to the following: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort.\n\n* Prior Therapy Restrictions Completion of previous chemotherapy, immunotherapy, radiotherapy, or targeted therapy for LCH (or other histiocytic disorder) at least 28 days (except where specified below) prior to study enrollment, with resolution of all associated toxicity to ≤ Grade 1 prior to study enrollment (exception for alopecia and ototoxicity which do not need to be resolved ≤ Grade 1). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the laboratory eligibility criteria are met, the patient is considered to have recovered adequately. See below for specific consideration of prednisone and corticosteroids prior to enrollment.\n\n  * Radiation therapy within the 14 days prior to enrollment.\n  * Any prior treatment with Cobimetinib.\n  * Treatment with a long-acting hematopoietic growth factor within 14 days prior to initiation of study drug or a short-acting hematopoietic growth factor within 7 days prior to enrollment.\n  * Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives), immunotherapy, biologic therapy, investigational therapy, or herbal cancer therapy within 28 days or \\\u003C 5 half-lives, whichever is longer, prior to study enrollment.\n  * Treatment with high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant) or allogeneic stem cell transplant within 90 days prior to enrollment. Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.\n  * For patients with brain tumors (intracranial masses), use of anticoagulants within 7 days prior to enrollment.\n  * Corticosteroid therapy less than or equal to 0.5 mg\u002Fkg\u002Fday averaged during the 28 days prior to study enrollment is permissible. Patients receiving corticosteroids must be on a stable or decreasing dose for 14 days prior to enrollment and discontinue once study treatment has started.\n  * Patient has received treatment with investigational therapy within 4 weeks prior to initiation of study drug.\n  * Patients taking anticoagulants or have a pre-existing bleeding disorder unrelated to histiocytic disease.\n* Exclusions for other illness\n\n  * Other active malignancy or history of secondary malignancy.\n  * Refractory nausea and vomiting, malabsorption, external biliary shunt\n  * Infection: Patients who have a known active infection (excluding documented fungal infection of the nail beds) within 28 days prior to enrollment that has not completely resolved.\n  * Major surgical procedure or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days prior to study enrollment (provided that the wound has healed).\n  * History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease.\n  * History of pneumonitis.\n  * Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion are not eligible. Specifically, patients with a history of retinal vein occlusion (RVO), retinal detachment, retinal pathology on ophthalmologic exam, retinopathy of prematurity, central serous chorioretinopathy (CSSCR), neovascular retinopathy, intraocular pressure \\> 21 mmHg, and predisposing factors to RVO (e.g., uncontrolled hypertension, diabetes, or hyperlipidemia, coagulopathy) will be excluded. Patients with longstanding and stable ophthalmologic findings secondary to existing conditions are eligible with appropriate written documentation and approval from Study Chair.\n  * History of solid organ transplantation: Patients who have received a prior solid organ transplantation are not eligible.\n  * Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates use of an investigational drug or places the patient at unacceptable risk from treatment complications.\n* History of clinically significant cardiac dysfunction, including the following:\n\n  * Clinically significant cardiac arrhythmias including brady-arrhythmias and\u002For patients who require anti-arrhythmic therapy (with the exception of beta blockers or digoxin). Patients with controlled atrial fibrillation are not excluded.\n  * Unstable arrhythmia\n  * Unstable angina, or new-onset angina within 3 months prior to initiation of study treatment\n  * Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher\n  * Myocardial infarction within 3 months prior to initiation of study treatment\n* Known chronic human immunodeficiency virus (HIV).\n* History of Grade ≥ 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of enrollment.\n* Female patients who are pregnant or lactating. Pregnant or lactating women will not be entered on this study because there is no available information regarding human fetal or teratogenic toxicities.",{"count":258,"type":20},90,[134],"This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.",[262,263,264,265,26,266,267],"Langerhan's Cell Histiocytosis","Juvenile Xanthogranuloma","Erdheim-Chester Disease","Rosai Dorfman Disease","Histiocytic Sarcoma","Histiocytic Disorders, Malignant",[269,270],"Cobimetinib","Langerhans Cell Histiocytosis (LCH)","2025-09-12",{"date":273,"type":31},"2025-09-18",{"date":275,"type":31},"2021-04-19",{"date":277,"type":20},"2029-12",{"name":279,"class":38},"Carl Allen",12,{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":47,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":289,"conditions":290,"keywords":296,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":94},"100602692","a-vision-language-foundation-model-for-brain-disease-diagnosis-from-multimodal-data-100602692","NCT07126821","A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","Inclusion Criteria:\n\nPatients with brain diseases:\n\n* Patients with brain tumors were pathologically diagnosed.\n* Patients with other brain diseases were correctly diagnosed.\n* The clinical case data of all patients were complete.\n\nNon-brain disease population:\n\n* All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.\n\nExclusion Criteria:\n\n* Cases in which MRI were incomplete or with significant noise and artifacts.",{"count":288,"type":20},100000,"The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.",[291,292,26,293,294,295],"Brain (Nervous System) Cancers","Brain Arterial Disease","Brain Tumors","Brain Diseases","Neurological di",[297,298,299,300,301,302,303],"brain tumors","brain cancers","brain diseases","foundation model","diagnosis","prediction","neurological diseases","2025-08-15",{"date":306,"type":31},"2025-08-17",{"date":308,"type":31},"2025-05-15",{"date":310,"type":20},"2030-12-31",{"name":312,"class":38},"Xiangya Hospital of Central South University",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":322,"conditions":323,"keywords":329,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":94},"100430075","longitudinal-study-of-ultra-rare-inherited-metabolic-and-degenerative-neurological-diseases-100430075","NCT04880356","Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.","Clinical, Instrumental and Laboratory Data Collection of Subjects with Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Subjects with ultra-rare inherited degenerative and metabolic neurological diseases\n* Subjects with undiagnosed neurological diseases (when supposed to be inherited)\n\nExclusion Criteria:\n\n* none",{"count":321,"type":20},100,"General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.",[324,325,326,327,328,26],"Inherited Disease","Rare Diseases","Metabolic Disease","Undiagnosed Disease","Neurologic Disorder",[330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351],"Leukodystrophies,","Adrenoleukodystrophy,","Metachromatic leukodystrophy,","Krabbe disease,","Vanishing White Matter Syndrome,","Alexander disease,","Hereditary Leukodystrophy with Spheroids (CSF1R-related HLDS),","Nasu-Hakola disease (TREM2- and TYROBP-related disease)","Leukoencephalopathy, progressive, with ovarian failure (LKENP, AARS2-related),","Pelizaeus-Merzbacher disease,","Pelizaeus-Merzbacher-like disease,","Hypomyelinating leukodystrophies,","Leukodystrophies with calcifications and cysts (LCC),","Leukoencephalopathy with ataxia disease (LKPAT, CLCN2-related),","L-2-Hydroxyglutaric aciduria,","Polyglucosan bodies disease,","Methylmalonic acidemia with homocystinuria,","Niemann-pick type C,","Fahr's disease,","Wilson's disease,","Cerebrotendinous Xanthomatosis,","Sphingolipidoses","2024-11-15",{"date":354,"type":31},"2024-11-19",{"date":356,"type":31},"2021-03-01",{"date":358,"type":20},"2031-03",{"name":360,"class":38},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":370,"conditions":371,"keywords":387,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":4},"100557135","digital-diagnostics-and-intervention-services-for-parkinsons-disease-100557135","NCT06534177","Digital Diagnostics and Intervention Services for Parkinson's Disease","Development of Digital Diagnostics and Intervention Services for Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \\[stroke, multiple sclerosis, arthritis or osteoporosis\\]\n* Able to self-report history of daily gait freezing and\u002For festination for people with PD or gait and\u002For transfers affected by condition\n* Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands Healthy participants \\[Phase 1,2,3\\]\n* With no long-term conditions affecting movement\n* Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and\n* if over 69 used to carrying out this level of exercise\n* Adult (+18 years old)\n* Normal or corrected-to-normal vision (Snellen Visual Acuity \\> 12\u002F18) or safe to mobilise with support\n* Montreal Cognitive assessment score \\>21 or ability to follow 2 stage commands\n\nExclusion Criteria:\n\n* Participants with long-term conditions affecting movement\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system Healthy participants\n* Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand\n* testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team.\n* Cognitive impairment affecting ability to safely participate and follow instructions\n* Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind knee area\n* Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system",{"count":369,"type":20},80,"People with Parkinson's have infrequent clinical consultation (once every 12-18 months) and limited rehabilitation.\n\nAssessment play an important role in these consultations to help clinicians understand patients' health status and disease progression necessary to adjust treatment plans. The current way of measuring is the UPDRS which needs a clinician to do this and takes 30 minutes. There is a strong need for more frequent and accurate Parkinson's assessments in the clinic and at home to detect changes early and then give appropriate support and drug and physiotherapy quickly. There is a need to develop good home digital physiotherapy tools to increase the amount of therapy. Here the investigators are testing new digital technologies to do these assessments in the home and clinic and a new digital physiotherapy device in the home. The investigators aim to conduct a clinical study with 50 people with Parkinson's (50 from UK) with the UPDRS, (a rating scale that is commonly used in clinical settings to evaluate the progression of Parkinson's disease) and 30 healthy adults. The investigators will develop and investigate if two new digital devices, one the MachineMD that measures eye movement and one the gaitQ that measures gait can be used instead of the MDS-UPDRS (motor) using digital gait and ophthalmic features in the clinic setting. The investigators will investigate the effect of a physiotherapy gait intervention gaitQ Tempo in the home context for two weeks and of doing the gait measure at home. The investigators will determine the potential of the gaitQ intervention to improve key gait metrics in order to collect clinical evidence and of using the gaitQ as a cuing system over a 2-week period on gait and other movement measures in the home and community",[294,372,373,374,60,375,376,377,378,26,379,380,381,382,383,384,385,386,165],"Central Nervous System Diseases","Nervous System Diseases","Joint Diseases","Parkinson Disease","Basal Ganglia Diseases","Movement Disorders","Synucleinopathies","Demyelinating Disease, Autoimmune, CNS","Demyelinating Disease","Autoimmune Diseases","Immune System Diseases","Bone Diseases, Metabolic","Bone Diseases","Arthritis","Osteoporosis",[388,389,390,391,392],"parkinson's disease","osteoarthritis","stroke","MS","osteoporosis","2024-08-06",{"date":395,"type":31},"2024-08-09",{"date":397,"type":20},"2024-10-15",{"date":399,"type":20},"2026-03-01",{"name":401,"class":38},"University of Exeter",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":21,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":94},"100297566","3t-mri-in-patients-with-deep-brain-stimulation-dbs-100297566","NCT03153670","3T MRI in Patients With Deep Brain Stimulation (DBS)","Inclusion Criteria:\n\n* Age between 18 and 85 years of age\n* Participants must be planned to undergo, or have undergone implantation of DBS electrodes\n* Participants must be able to understand the purpose of this research and must sign the informed consent form.\n* Participants must understand that the role of this research is to enhance our understanding of brain functioning and that he\u002Fshe will not directly or indirectly benefit from the study.\n\nExclusion Criteria:\n\n* Participants who have serious cognitive or psychological impairments and cannot give informed consent.\n* Participants who are unable to effectively or efficiently communicate, for example patients suffering from speech deficits (dysarthria, aphasia) or are non-English speaking.","85 Years",{"count":410,"type":20},250,[23],"Deep brain stimulation (DBS) is an established treatment for advanced Parkinson's disease, medically refractory tremor, dystonia and obsessive compulsive disorder. Several hypotheses driven DBS trials are underway to study modulation of circuit dysfunction in other neurological and psychiatric disorders like epilepsy, Alzheimer's disease and depression. Recent reports suggest profound effects of DBS on the anatomy and function of downstream areas in the brain. For example electrical stimulation of limbic circuits is associated with increase in hippocampal neurogenesis. Similarly, stimulation of subthalamic nucleus (STN) or globus pallidus (GPi) results in activation of cortical motor circuits. Non-invasive imaging modalities are increasingly being employed in these investigations to better understand the effects of DBS on the structure and function of the brain.\n\nThere have been important advances in MRI and we now have MRI which provides higher resolution and higher quality brain images. More specifically, the investigators propose to use MRI to perform functional magnetic resonance imaging (i.e. fMRI) to assess the effects of deep brain stimulation on brain function and to assess whether fMRI can be used as an adjunct to improve clinical practice in these patients.",[26],"2024-05-07",{"date":416,"type":31},"2024-05-08",{"date":418,"type":31},"2017-06-01",{"date":420,"type":20},"2030-12-01",{"name":422,"class":38},"University Health Network, Toronto",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":47,"sex":16,"minAge":430,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":94},"100489632","identifying-biomarkers-in-alzheimers-disease-100489632","NCT05655650","Identifying Biomarkers in Alzheimer's Disease","SEEDS","Inclusion Criteria:\n\n* Chinese ethnicity\n* \\[For dementia group, clinical diagnosis of \"probable Alzheimer's disease\" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA)\n\nExclusion Criteria:\n\n* Clinical diagnosis of non-AD dementia\n* contraindication for MRI or PET","20 Years",{"count":432,"type":20},300,"Alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. With the ageing population, AD is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. AD is the only cause of death among the top ten causes that has no prevention or cure . It is believed that novel treatment of AD needs to start early or even at the prodromal stage in order to be effective. Therefore, there is an urgent need to find accurate methods of early detection before patients with AD develop clinical dementia.\n\nThis study aims to identify biomarkers for AD in local Chinese population. this study hypothesizes blood-based proteomics, retinal imaging, ASL-MRP and tau PET can improve the accuracy and staging of AD.",[26,435],"Alzheimer Disease",[435],"2022-12-09",{"date":439,"type":31},"2022-12-19",{"date":441,"type":31},"2018-09-01",{"date":310,"type":20},{"name":444,"class":38},"Chinese University of Hong Kong"]